Arcus Biosciences to present new data from Casdatifan at 2025 ASCO

Arcus Biosciences (RCUS) “announced that data from the ARC-20 study will be presented in a rapid oral session at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium taking place February 13 – 15, 2025, in San Francisco, CA. The oral presentation will highlight safety and efficacy data from three cohorts of ARC-20, which evaluated casdatifan monotherapy in patients that had received both prior TKI and anti-PD-1 therapy. The presentation will include initial data for the 100mg QD tablet cohort, our selected dose and formulation for Arcus’s Phase 3 studies, as well as updated data for the 50mg BID and 50mg QD expansion cohorts of ARC-20.”